Table 4 Base case results by disease severity for the 10 years following treatment initiation*
Patients with MMSE ≥ 10 and ≤ 26 versus untreated patients | Untreated | Donepezil | Net difference |
|---|---|---|---|
Survival (undiscounted, in years) | 4,870 | 4,870 | 0,000 |
Drug Costs | € 0 | € 4,625 | €4,625 |
Total Non-Drug Direct Costs | €126,863 | €115,231 | -€11,632 |
Total Direct Costs | €126,863 | €119,856 | -€7,007 |
Indirect Costs | €87,138 | €84,253 | -€2,885 |
Total Costs | €214,001 | €204,108 | -€9,893 |
Years with MMSE > 10 | 1,972 | 2,435 | 0,463 |
Years with NPI < 28 | 2,680 | 2,794 | 0,114 |
Years with ADL < 50 | 1,896 | 2,036 | 0,140 |
Years with IADL < 50 | 0,241 | 0,303 | 0,062 |
Years in Institution | 1,663 | 1,457 | -0,206 |
Total Care Time (Years) | 1,908 | 1,845 | -0,063 |
QALYs (Patient) | 1,659 | 1,790 | 0,131 |
QALYs (Caregiver) | 3,272 | 3,287 | 0,014 |
QALYS (Patient + Caregiver) | 4,931 | 5,077 | 0,146 |
Health Care Direct Cost/QALY (Patient + Caregiver) | Â | Dominant | |
Societal Total Cost/QALY (Patient +Caregiver) | Â | Dominant | |
Patients with MMSE ≥ 10 and < 20 versus memantine | Memantine | Donepezil | Net difference |
Survival (undiscounted, in years) | 4,909 | 4,909 | 0,000 |
Drug Costs | €4,972 | €4,696 | -€276 |
Total Non-Drug Direct Costs | €129,702 | €128,019 | -€1,684 |
Total Direct Costs | €134,674 | €132,715 | -€1,960 |
Indirect Costs | €89,572 | €88,707 | -€ 865 |
Total Costs | €224,246 | €221,422 | -€2,825 |
Years with MMSE > 10 | 2,023 | 2,801 | 0,058 |
Years with NPI < 28 | 2,808 | 2,751 | -0,058 |
Years with ADL < 50 | 1,772 | 1,835 | 0,062 |
Years with IADL < 50 | 0,186 | 0,209 | 0,023 |
Years in Institution | 1,702 | 1,673 | -0,028 |
Total Care Time (Years) | 1,961 | 1,942 | -0,019 |
QALYs (Patient) | 1,663 | 1,677 | 0,014 |
QALYs (Caregiver) | 3,276 | 3,279 | 0,003 |
QALYS (Patient + Caregiver) | 4,939 | 4,956 | 0,017 |
Health Care Direct Cost/QALY (Patient + Caregiver) | Â | Dominant | |
Societal Total Cost/QALY (Patient +Caregiver) | Â | Dominant | |